SHIELD
Trial overview
To evaluate the efficacy and toxicity of VEPEMB in a phase II study in older patients with Hodgkins Lymphoma (HL). A number of older patients with HL fail to enter clinical trials as they are "not fit" for multiple drug chemotherapy. This study will aim to include all pathologically eligible patients in participating centres in order to provide a clearer overall clinical picture of this disease, whether or not they undergo protocol chemotherapy.
Inclusion criteria
Histological confirmed classical Hodgkin Lymphoma (HL)
No previous treatment for HL
Age ≥60
No concomitant neoplasia requiring treatment or known HIV infection
Written informed consent
Exclusion criteria
Nodular lymphocyte predominance Hodgkin Lymphoma (NLPHL)
Age <60
Patient previously treated for HL
Known HIV infection or concomitant neoplasia
"Fragile patient" or significant abnormality of another system (pulmonary, cardiac, renal and hepatic) which is a contraindication to full dose chemotherapy
Unable to give informed consent
Contact details
Other trials currently active for Classical Hodgkin Lymphoma
A RANDOMISED PHASE III TRIAL TO
ASSESS RESPONSE ADAPTED
THERAPY USING FDG-PET IMAGING
IN PATIENTS WITH NEWLY
DIAGNOSED, ADVANCED HODGKIN
LYMPHOMA
A randomised phase III trial to determine the role of FDG-P imaging in clinical stages IA/IIA Hodgkins disease.